个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Yang Libo[1,2] * ; Shen Mengjia[1,2] ; Qiu Yan[1,2] ; Tang Tingting[1,2] ; Bu Hong[1,2,*1] ;
机构： [1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China [2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China
出处：
DOI： 10.1016/j.breast.2022.03.019
ISSN：

关键词： Ductal Carcinoma in situ Molecular subtype Lumpectomy Recurrence

摘要：
We aimed to analyse the discrepancy in clinical features and prognosis between molecular subtypes in primary ductal carcinoma in situ (DCIS) patients with lumpectomy.Primary DCIS patients were identified from the Surveillance, Epidemiology, and End Results registries database from 2010 to 2017. Based on immunohistochemistry markers of hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2), enrolled DCIS cases were divided into four molecular subtypes, HR-HER2-, HR-HER2+, HR + HER2+, and HR + HER2-. Clinical features and prognosis were compared between molecular subtypes. Radiotherapy (RT) effects on prognosis were also analysed in each molecular subtype.A total of 5,628 DCIS cases were retrospectively enrolled in this study. HR-HER2-, HR-HER2+, HR+HER2+, and HR+HER2- are 299 (5.3%), 498 (8.8%), 1,086 (19.3%), and 3,745 (66.5%), respectively. HR + HER2- cases have smaller tumor size (72.6%, P < 0.001) and lower grade (23.5%, P < 0.001). Comedo necrosis is more frequent in HR-HER2- (24.4%, P < 0.001) and HR-HER2+ DCIS cases (24.3%, P < 0.001). In univariate analyses, HR-HER2+ cases have significantly higher ipsilateral breast event (IBE) recurrence than HR+HER2- cases (P = 0.010). HR-HER2- cases show higher disease-specific mortality than HR+HER2+ cases (P = 0.021). In high-risk DCIS cases, RT reduces the absolute 5-year IBE incidence by 1.3%, 0.7%, 1.9%, and 2.6%, respectively in HR-HER2-, HR-HER2+, HR+HER2+, and HR+HER2- cases, respectively.In this population-based study, DCIS cases have diverse clinical and prognostic features for different molecular subtypes. Adjusting treatment strategies according to DCIS molecular subtypes is worth advancing.Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

基金：
Post-Doctor Research Project, West China Hospital, Sichuan University (2021HXBH024), the 1.3.5 Project for disciplines of excellence (ZYGD18012), and Postdoctoral Science Foundation of China (2021M692267)
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 2 区 医学
小类 | 2 区 妇产科学 3 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 妇产科学 3 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China [2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China
通讯作者：
通讯机构： [1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China [2]Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, China [*1]Department of Pathology, West China Hospital, Sichuan University, Guo Xue Xiang 37 Hao, Chengdu City, 610041, Sichuan Province, China.
推荐引用方式(GB/T 7714)：
Yang Libo,Shen Mengjia,Qiu Yan,et al.Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.[J].Breast (Edinburgh, Scotland).2022,64:1-6.doi:10.1016/j.breast.2022.03.019.
APA：
Yang Libo,Shen Mengjia,Qiu Yan,Tang Tingting&Bu Hong.(2022).Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy..Breast (Edinburgh, Scotland),64,
MLA：
Yang Libo,et al."Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.".Breast (Edinburgh, Scotland) 64.(2022):1-6

相关文献

[1]Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. [2]Preoperative prediction of extensive intraductal component in invasive breast cancer based on intra- and peri-tumoral heterogeneity in high-resolution ultrafast DCE-MRI [3]Prediction of coexisting invasive carcinoma on ductal carcinoma in situ (DCIS) lesions by mass spectrometry imaging [4]Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation(Open Access) [5]Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast [6]Breast cancer cells interact with tumor-derived extracellular matrix in a molecular subtype-specific manner [7]放疗对改良根治术后T1～T2期伴1～3个腋窝淋巴结转移乳腺癌不同分子亚型患者预后影响 [8]Mitochondria Dysfunction-Mediated Molecular Subtypes and Gene Prognostic Index for Prostate Cancer Patients Undergoing Radical Prostatectomy or Radiotherapy. [9]CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer [10]Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

资源点击量：53080 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号